Lupin and Boehringer Ingelheim inked a licensing, development and commercialisation agreement in 2019 for the Indain company#39;s novel oncology compound for difficult-to-treat cancers.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment